John Fung to Heart Transplantation
This is a "connection" page, showing publications John Fung has written about Heart Transplantation.
Connection Strength
2.107
-
Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. J Heart Lung Transplant. 2019 09; 38(9):997-999.
Score: 0.112
-
I-131 orthoiodohippurate assessment of renal function after heart transplantation. Clin Nucl Med. 1999 Feb; 24(2):117-9.
Score: 0.109
-
Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts. Immunology. 1996 May; 88(1):124-9.
Score: 0.090
-
FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. Transplant Proc. 1994 Jun; 26(3):1211.
Score: 0.079
-
The effect of splenectomy on cardiac and liver xenografts in the nude rat. Transplant Proc. 1994 Jun; 26(3):1210.
Score: 0.079
-
Liver graft induced donor specific unresponsiveness without class I and/or class II antigen differences. Transplant Proc. 1993 Feb; 25(1 Pt 1):362-3.
Score: 0.072
-
Combined heart and liver transplantation: the Cleveland Clinic experience. Ann Thorac Surg. 2013 Jan; 95(1):179-82.
Score: 0.071
-
Overview of FK506 in transplantation. Clin Transpl. 1990; 115-21.
Score: 0.058
-
Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus. J Heart Lung Transplant. 2006 Mar; 25(3):310-9.
Score: 0.044
-
Regulatory dendritic cells modulate immune responses via induction of T-cell apoptotic death. Microsurgery. 2006; 26(1):21-4.
Score: 0.044
-
Immune regulatory activity of liver-derived dendritic cells generated in vivo. Microsurgery. 2006; 26(1):17-20.
Score: 0.044
-
Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol. 1985 Nov; 14(3):287-94.
Score: 0.044
-
Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg. 2005 Mar; 241(3):497-505.
Score: 0.042
-
Minimal evidence of transdifferentiation from recipient bone marrow to parenchymal cells in regenerating and long-surviving human allografts. Am J Transplant. 2003 Sep; 3(9):1173-81.
Score: 0.038
-
Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation. 2003 Aug 27; 76(4):721-9.
Score: 0.037
-
Prolonged survival of heart allografts transduced with AAV-CTLA4Ig. Microsurgery. 2003; 23(5):489-93.
Score: 0.036
-
Administration of antisense oligodeoxyribonucleotides targeting NF-kappaB prolongs allograft survival via suppression of cytotoxicity. Microsurgery. 2003; 23(5):494-7.
Score: 0.036
-
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol. 2002 Sep 15; 169(6):3382-91.
Score: 0.035
-
Transfection with genes encoding CTLA4Ig mediated by adenoassociated virus vectors prolongs survival of heart allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):604.
Score: 0.031
-
Use of non-heart-beating donors. Transplant Proc. 2000 Nov; 32(7):1510-1.
Score: 0.031
-
Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther. 2000 May; 1(5 Pt 1):430-7.
Score: 0.030
-
A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 2000 Apr; 119(4 Pt 1):673-81.
Score: 0.030
-
Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function. Transplantation. 1999 Nov 15; 68(9):1402-9.
Score: 0.029
-
Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation. 1999 Sep 27; 68(6):747-57.
Score: 0.029
-
Recipient pretreatment with mammalian IL-10 prolongs mouse cardiac allograft survival by inhibition of anti-donor T cell responses. Transplant Proc. 1999 Feb-Mar; 31(1-2):115.
Score: 0.027
-
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation. 1997 Dec 27; 64(12):1808-15.
Score: 0.025
-
High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1081-2.
Score: 0.024
-
Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts. Transplant Proc. 1997 Feb-Mar; 29(1-2):1310.
Score: 0.024
-
Donor-specific transfusion in the nude rat prolongs survival of subsequently transplanted hamster cardiac xenografts. Transplant Proc. 1997 Feb-Mar; 29(1-2):928-9.
Score: 0.024
-
Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant. 1997; 2(2):27-44.
Score: 0.024
-
Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation. 1996 Dec 27; 62(12):1709-14.
Score: 0.024
-
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation. 1996 Sep 15; 62(5):659-65.
Score: 0.023
-
The antigenicity of serum proteins and their role in xenograft rejection. Transplant Proc. 1996 Apr; 28(2):669-70.
Score: 0.022
-
Pretreatment of recipients (nude rat) with donor antigens leads to prolonged survival of hamster heart xenografts. Transplant Proc. 1996 Apr; 28(2):696-7.
Score: 0.022
-
Use of MHC class I or II "knock out" mice to delineate the role of these molecules in acceptance/rejection of xenografts. Transplant Proc. 1996 Apr; 28(2):732.
Score: 0.022
-
Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. Transplant Proc. 1996 Apr; 28(2):733-4.
Score: 0.022
-
Perioperative treatment with phosphatidic acid inhibitor (Lisofylline leads to prolonged survival of hearts in the guinea pig to rat xenotransplant model. Transplant Proc. 1996 Apr; 28(2):738-9.
Score: 0.022
-
Presensitization by skin grafting from major histocompatibility complex class I or major histocompatibility complex class II deficient mice identifies class I antigens as inducers of allosensitization. Immunology. 1995 May; 85(1):82-7.
Score: 0.021
-
Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. Transplant Proc. 1995 Feb; 27(1):277.
Score: 0.021
-
Mechanisms of protection from humoral rejection by a xenografted liver. Transplant Proc. 1995 Feb; 27(1):300-2.
Score: 0.021
-
Propagation of cells expressing donor phenotype (MHC class I, II and Y-chromosome) from the bone marrow of murine liver allograft recipients in response to GM-CSF in vitro. Transplant Proc. 1995 Feb; 27(1):191-3.
Score: 0.021
-
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc. 1993 Dec; 25(6):3337-44.
Score: 0.019
-
Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation. 1993 Aug; 56(2):482-4.
Score: 0.019
-
Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol. 1993 Jul; 143(1):85-98.
Score: 0.019
-
Induction of donor-specific transplantation tolerance to skin and cardiac allografts using mixed chimerism in (A + B-->A) in rats. Cell Transplant. 1993 Jul-Aug; 2(4):345-53.
Score: 0.019
-
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation. 1993 Mar; 55(3):659-61.
Score: 0.018
-
Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. Transplant Proc. 1993 Feb; 25(1 Pt 1):414-5.
Score: 0.018
-
Two-year experience with FK 506 in pediatric patients. Transplant Proc. 1993 Feb; 25(1 Pt 1):619-21.
Score: 0.018
-
Long-term survival of heart and liver xenografts with splenectomy and FK 506. Transplant Proc. 1993 Feb; 25(1 Pt 1):647-8.
Score: 0.018
-
Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. Transplant Proc. 1992 Aug; 24(4):1403-5.
Score: 0.017
-
Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis. 1992 Feb; 12(1):51-9.
Score: 0.017
-
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3269-71.
Score: 0.017
-
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc. 1991 Dec; 23(6):3322-4.
Score: 0.017
-
The effect of thymus transplantation on allograft rejection in thymectomized bone marrow chimeras. Transplant Proc. 1990 Dec; 22(6):2536-8.
Score: 0.016
-
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990 Aug; 50(2):186-9.
Score: 0.015
-
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):25-34.
Score: 0.015
-
Transplant innovation and ethical challenges: what have we learned? A collection of perspectives and panel discussion. Cleve Clin J Med. 2008 Nov; 75 Suppl 6:S24-9; discussion S30-2.
Score: 0.013
-
Bronchoalveolar macrophage-lymphocyte reactivity in heart-lung transplant recipients. Transplant Proc. 1987 Feb; 19(1 Pt 3):2537-40.
Score: 0.012
-
Sequential infiltration of class I and class II specific alloreactive T cells in human cardiac allografts. Transplant Proc. 1987 Feb; 19(1 Pt 3):2560-3.
Score: 0.012
-
In vivo expansion of two distinct dendritic cells in mouse livers and its impact on liver immune regulation. Liver Transpl. 2006 Dec; 12(12):1850-61.
Score: 0.012
-
Functional studies of in vivo committed lymphocytes propagated from organ transplants. Prog Clin Biol Res. 1986; 211:59-73.
Score: 0.011
-
Lymphocytes of bronchoalveolar lavages from heart-lung transplant recipients. J Heart Transplant. 1985 Jul-Aug; 4(4):417-21.
Score: 0.011
-
Application of recipient-derived dendritic cells to induce donor-specific T-cell hyporesponsiveness. Transplant Proc. 2004 Jun; 36(5):1592-4.
Score: 0.010
-
Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J Immunol. 2004 Feb 01; 172(3):1355-63.
Score: 0.010
-
Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function. Transplant Proc. 2002 Aug; 34(5):1394-5.
Score: 0.009
-
Liver-derived DEC205+B220+CD19- dendritic cells regulate T cell responses. J Immunol. 2001 Jun 15; 166(12):7042-52.
Score: 0.008
-
Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA. Transplant Proc. 2001 Feb-Mar; 33(1-2):235.
Score: 0.008
-
Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology. 2000 Oct; 101(2):233-41.
Score: 0.008
-
Serum protein immunogenicity: implications for liver xenografting. Electrophoresis. 2000 Mar; 21(5):965-75.
Score: 0.007
-
Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol. 1999 Aug; 66(2):310-4.
Score: 0.007
-
Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients. Transplantation. 1998 Dec 27; 66(12):1587-96.
Score: 0.007
-
Cardiac operations in solid-organ transplant recipients. Ann Thorac Surg. 1997 Nov; 64(5):1270-8.
Score: 0.006
-
Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients. Transplant Proc. 1997 May; 29(3):1905-6.
Score: 0.006
-
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol. 1997 Feb; 150(2):563-78.
Score: 0.006
-
Augmentation of chimerism with perioperative donor bone marrow infusion in organ transplant recipients: a 44 month follow-up. Transplant Proc. 1997 Feb-Mar; 29(1-2):1184-5.
Score: 0.006
-
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med. 1995 Aug 01; 182(2):379-87.
Score: 0.005
-
Cytidine potentiates the inhibitory effect of brequinar sodium on concordant cardiac xenograft rejection. Transplant Proc. 1994 Jun; 26(3):1288-9.
Score: 0.005
-
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology. 1994 Apr; 19(4):916-24.
Score: 0.005
-
Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation. 1994 Mar 27; 57(6):918-22.
Score: 0.005
-
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992 Jun; 128(6):781-5.
Score: 0.004
-
[Clinical experience with FK 506]. Presse Med. 1991 Nov 27; 20(40):1967-73.
Score: 0.004
-
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991 Jul; 52(1):71-7.
Score: 0.004
-
Use of FK 506 in pediatric patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):924-7.
Score: 0.004
-
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990 Sep; 212(3):295-305; discussion 306-7.
Score: 0.004